In Brief: P&G
This article was originally published in The Tan Sheet
P&G: Intends to appeal U.S. District Court Judge Sue Robinson's Jan. 17 ruling that P&G's patent for 200 mg ibuprofen/30 mg pseudoephedrine for cough/cold products is not valid and enforceable ("The Tan Sheet" Jan. 22, p. 1). The ruling, which also says that defendants McNeil and Upjohn do not have to pay royalties on Motrin IB and Sine-Aid IB that contain the combination, reversed a jury decision in favor of P&G ("The Tan Sheet" May 22, 1995, p. 1). P&G also noted that the recent ruling does not affect its agreement with American Home Products, which licenses the combination for use in Dimetapp Sinus...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC